Satellos Bioscience Inc ICOTF

Primary Symbol: T.MSCL Alternate Symbol(s): MSCLF

Healthcare Biotechnology

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).

TSX:MSCL - Post by User

Satellos Bioscience Inc > Design of amphotericin B oral

<< Previous

Bullboard Posts

Next >>

Comment by curtismilleron Jun 21, 2018 10:09pm

110 Views

Post# 28210192

RE:RE:Design of amphotericin B oral

My prediction : 65c by mid July on top line results from phase 1 , followed by funding from big pharma and IND filed with FDA- 1.50 going into the fall in anticipation of more trials and possible designation from FDA.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing